ORBi: Detailled Reference

Article (Scientific journals)

Mesenchymal stromal cells : a new tool against graft-versus-host disease ?

Baron, Frédéric; Storb, Rainer

2012 • In Biology of Blood and Marrow Transplantation, 18 (6), p. 822-840

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/102042

DOI
10.1016/j.bbmt.2011.09.003

PubMed
21963621

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

MSC_HCT_Rev_BBMT12.pdf

Publisher postprint (506.1 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

mesenchymal stromal cells; MSC; graft-versus-host disease; GVHD; allogeneic hematopoietic cell transplantation

Abstract :

[en] Mesenchymal stromal cells (MSCs) represent a heterogeneous subset of multipotent cells that can be isolated from several tissues including bone marrow and fat. MSCs exhibit immunomodulatory and anti-inflammatory properties that prompted their clinical use as prevention and/or treatment for severe graft-versus-host disease (GVHD). Although a number of phase I-II studies have suggested that MSCs infusion was safe and might be effective for preventing or treating acute GVHD, definitive proof for their efficacy remains lacking thus far. Multicenter randomized studies are ongoing to more precisely assess the impact of MSCs infusion on GVHD prevention/treatment, whereas further research is performed in vitro and in animal models with the aims of determining the best way to expand MSCs ex vivo as well as the most efficient dose and schedule of MSCs administration. After introducing GVHD, MSC biology, and results of MSCs infusion in animal models of allogeneic hematopoietic cell transplantation, this article reviews the results of the first clinical trials investigating the use of MSCs infusion as prevention or treatment of GVHD.

Disciplines :

Hematology

Author, co-author :

Baron, Frédéric ; Université de Liège - ULiège > GIGA-R : Hématologie

Storb, Rainer

Language :

English

Title :

Mesenchymal stromal cells : a new tool against graft-versus-host disease ?

Publication date :

2012

Journal title :

Biology of Blood and Marrow Transplantation

ISSN :

1083-8791

eISSN :

1523-6536

Publisher :

Carden Jennings Publishing, Charlottesville, United States - Virginia

Volume :

18

Issue :

6

Pages :

822-840

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 09 November 2011

Statistics

Number of views

90 (4 by ULiège)

Number of downloads

313 (4 by ULiège)

More statistics

Scopus citations^®

85

Scopus citations^®
without self-citations

74

OpenCitations

72

OpenAlex citations

101

Bibliography

Baron F., Storb R. Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol 2004, 26:71-94.
Dickinson A.M., Wang X.N., Sviland L., et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 2002, 8:410-414.
Riddell S.R., Berger C., Murata M., Randolph S., Warren E.H. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Rev 2003, 17:153-162.
Kolb H.J., Schmidt C., Barrett A.J., Schendel D.J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103:767-776.
Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
Willemze R., Rodrigues C.A., Labopin M., et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009, 23:492-500.
Falkenburg J.H., Warren E.H. Graft versus leukemia reactivity after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:S33-S38.
Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300:1068-1073.
Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981, 304:1529-1533. Seattle Marrow Transplant Team.
Martin P.J., Hansen J.A., Torok-Storb B., et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988, 3:445-456.
Maraninchi D., Gluckman E., Blaise D., et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987, 2:175-178.
Goldman J.M., Gale R.P., Horowitz M.M., et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk of relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995, 23:1553-1562.
Collins R.H., Shpilberg O., Drobyski W.R., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997, 15:433-444.
Flowers M.E.D., Leisenring W., Beach K., et al. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. Biol Blood Marrow Transplant 2000, 6:321-326.
Sandmaier B.M., Mackinnon S., Childs R.W. Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant 2007, 13:87-97.
Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
Khouri I.F., Keating M., Körbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-2824.
McSweeney P.A., Niederwieser D., Shizuru J.A., et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-3400.
Chakraverty R., Peggs K., Chopra R., et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantion by using a nonmyeloablative conditioning regimen. Blood 2002, 99:1071-1078.
Maris M.B., Sandmaier B.M., Storer B.E., et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006, 12:454-465.
Baron F., Storb R., Storer B.E., et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006, 24:4150-4157.
Baron F., Sandmaier B.M., Storer B.E., et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 2007, 13:1041-1048.
Baron F., Petersdorf E.W., Gooley T., et al. What is the role for donor natural killer cells after nonmyeloablative conditioning?. Biol Blood Marrow Transplant 2009, 15:580-588.
Sullivan K.M. Graft-vs.-host disease. Thomas' Hematopoietic Cell Transplantation 2004, 635-664. Blackwell Publishing Ltd., Oxford, UK. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003, 102:756-762.
Childs R., Clave E., Contentin N., et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999, 94:3234-3241.
Baron F., Sandmaier B.M. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006, 20:1690-1700.
Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993-2003.
Valcarcel D., Martino R., Caballero D., et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008, 26:577-584.
Thepot S., Zhou J., Perrot A., et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010, 24:1852-1858.
Ferrara J.L., Levine J.E., Reddy P., Holler E. Graft-versus-host disease. Lancet 2009, 373:1550-1561.
Socie G., Blazar B.R. Acute graft-versus-host disease: from the bench to the bedside. Blood 2009, 114:4327-4336.
Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999, 285:412-415.
Kitko C.L., Paczesny S., Yanik G., et al. Plasma elevations of tumor necrosis factor-receptor-1 at day 7 postallogeneic transplant correlate with graft-versus-host disease severity and overall survival in pediatric patients. Biol Blood Marrow Transplant 2008, 14:759-765.
Choi S.W., Kitko C.L., Braun T., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
Willems E., Humblet-Baron S., Dengis O., Seidel L., Beguin Y., Baron F. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplant 2010, 45:1442-1448.
Paczesny S., Levine J.E., Braun T.M., Ferrara J.L. Plasma biomarkers in graft-versus-host disease: a new era?. Biol Blood Marrow Transplant 2009, 15:33-38.
Heimfeld S., Gooley T., Flowers M., et al. Effect of peripheral blood stem cell (PBSC) graft composition on graft versus host disease (GVHD) and mortality after allogeneic transplantation. ASH Annu Meet Abstr 2010, 116:676.
Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005, 23:3447-3454.
Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
Storb R., Doney K.C., Thomas E.D., et al. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. Blood 1982, 59:236-246.
Flowers M.E., Inamoto Y., Carpenter P.A., et al. Comparative analysis of risk factors for acute and for chronic graft-versus-host-disease according to National Institutes of Health consensus criteria. Blood 2011, 117:3214-3219.
Randolph S.S.B., Gooley T.A., Warren E.H., Appelbaum F.R., Riddell S.R. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic cell transplants. Blood 2004, 103:347-352.
Nguyen V.H., Zeiser R., Negrin R.S. Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006, 12:995-1009.
Colonna L., Sega E.I., Negrin R.S. Natural and expanded CD4(+)CD25(+) regulatory T cells in bone marrow transplantation. Biol Blood Marrow Transplant 2011, 17:S58-S62.
Castermans E., Hannon M., Dutrieux J., et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica 2011, 96:298-306.
Socie G. Chronic GVHD: B cells come of age. Blood 2011, 117:2086-2087.
Tsoi M.-S., Storb R., Jones E., et al. Deposition of IgM and complement at the dermo-epidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol 1978, 120:1485-1492.
Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005, 105:2973-2978.
Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28-35.
Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108:756-762.
Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986, 314:729-735.
Sorror M.L., Leisenring W., Deeg H.J., Martin P.J., Storb R. Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11:567-568.
Sorror M.L., Leisenring W., Deeg H.J., Martin P.J., Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant 2005, 11:814-815.
Storb R., Antin J.H., Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?. Biol Blood Marrow Transplant 2010, 16:S18-S27.
Mohty M., Bay J.O., Faucher C., et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003, 102:470-476.
Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
Deeg H.J., Storer B.E., Boeckh M., et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006, 12:573-584.
Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
Ho V.T., Aldridge J., Kim H.T., et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:844-850.
Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
Mielcarek M., Storer B.E., Boeckh M., et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood 2009, 113:2888-2894.
Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. Blood 1990, 76:1464-1472.
MacMillan M.L., Weisdorf D.J., Wagner J.E., et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002, 8:387-394.
Arai S.M. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:155-160.
Wolff D., Gerbitz A., Ayuk F., et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010, 16:1611-1628.
Martin P.J., Storer B.E., Rowley S.D., et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009, 113:5074-5082.
Rezvani A.R., Leisenring W., Martin P.L., et al. Duration of immunosuppressive therapy for chronic graft-vs.-host disease (cGVHD) following non-myeloablative allogeneic hematopoietic cell transplantation (HCT). ASH Annu Meet Abstr 2007, 110:1071.
Lee S.J., Vogelsang G., Flowers M.E.D. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
Lee S.J., Flowers M.E. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 134-141.
Wolff D., Schleuning M., von Harsdorf S., et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011, 17:1-17.
Jones E.A., Kinsey S.E., English A., et al. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 2002, 46:3349-3360.
Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
Friedenstein A.J., Petrakova K.V., Kurolesova A.I., Frolova G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968, 6:230-247.
Friedenstein A.J., Deriglasova U.F., Kulagina N.N., et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 1974, 2:83-92.
Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:321-334.
Nauta A.J., Fibbe W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007, 110:3499-3506.
Tolar J., Le Blanc K., Keating A., Blazar B.R. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010, 28:1446-1455.
Salem H.K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010, 28:585-596.
Sundin M., Ringden O., Sundberg B., Nava S., Gotherstrom C., Le Blanc K. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007, 92:1208-1215.
Sundin M., Barrett A.J., Ringden O., et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 2009, 32:755-764.
Di Nicola M., Carlo-Stella C., Magni M., et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99:3838-3843.
Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003, 57:11-20.
Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008, 112:532-541.
Maccario R., Podesta M., Moretta A., et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90:516-525.
Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006, 107:1484-1490.
Corcione A., Benvenuto F., Ferretti E., et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107:367-372.
Traggiai E., Volpi S., Schena F., et al. Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 2008, 26:562-569.
Mielcarek M., Storb R., Georges G.E., et al. Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog-leukocyte-antigen haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2011, 17:214-225.
Nasef A., Mathieu N., Chapel A., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
Selmani Z., Naji A., Zidi I., et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008, 26:212-222.
Gieseke F., Bohringer J., Bussolari R., Dominici M., Handgretinger R., Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116:3770-3779.
Mougiakakos D., Jitschin R., Johansson C.C., Okita R., Kiessling R., Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011, 117:4826-4835.
Glennie S., Soeiro I., Dyson P.J., Lam E.W., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
Jiang X.X., Zhang Y., Liu B., et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105:4120-4126.
Spaggiari G.M., Abdelrazik H., Becchetti F., Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009, 113:6576-6583.
Zhang B., Liu R., Shi D., et al. Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 2009, 113:46-57.
Casiraghi F., Azzollini N., Cassis P., et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J Immunol 2008, 181:3933-3946.
Djouad F., Plence P., Bony C., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102:3837-3844.
Gonzalez M.A., Gonzalez-Rey E., Rico L., Buscher D., Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009, 136:978-989.
Parekkadan B., Tilles A.W., Yarmush M.L. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells 2008, 26:1913-1919.
Zappia E., Casazza S., Pedemonte E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
Djouad F., Fritz V., Apparailly F., et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 2005, 52:1595-1603.
Bartholomew A., Sturgeon C., Siatskas M., et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002, 30:42-48.
Roecklein B.A., Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood 1995, 85:997-1005.
Majumdar M.K., Thiede M.A., Haynesworth S.E., Bruder S.P., Gerson S.L. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000, 9:841-848.
Graf L., Iwata M., Torok-Storb B. Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a. Blood 2002, 100:1509-1511.
Iwata M., Awaya N., Graf L., Kahl C., Torok-Storb B. Human marrow stromal cells activate monocytes to secrete osteopontin, which down-regulates Notch1 gene expression in CD34+ cells. Blood 2004, 103:4496-4502.
Dazzi F., Ramasamy R., Glennie S., Jones S.P., Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev 2006, 20:161-171.
Wynn R.F., Hart C.A., Corradi-Perini C., et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004, 104:2643-2645.
Mouiseddine M., Francois S., Semont A., et al. Human mesenchymal stem cells home specifically to radiation-injured tissues in a non-obese diabetes/severe combined immunodeficiency mouse model. Br J Radiol 2007, 80(Spec No 1):S49-S55.
Spaeth E., Klopp A., Dembinski J., Andreeff M., Marini F. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008, 15:730-738.
Noort W.A., Kruisselbrink A.B., In't Anker P.S., et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2002, 30:870-878.
Maitra B., Szekely E., Gjini K., et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004, 33:597-604.
Briquet A., Dubois S., Bekaert S., Dolhet M., Beguin Y., Gothot A. Prolonged ex vivo culture of human bone marrow mesenchymal stem cells influences their supportive activity toward NOD/SCID-repopulating cells and committed progenitor cells of B lymphoid and myeloid lineages. Haematologica 2010, 95:47-56.
Mattsson J., Ringden O., Storb R. Graft failure after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:165-170.
Nauta A.J., Westerhuis G., Kruisselbrink A.B., Lurvink E.G., Willemze R., Fibbe W.E. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006, 108:2114-2120.
Sudres M., Norol F., Trenado A., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006, 176:7761-7767.
Miura M., Miura Y., Padilla-Nash H.M., et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-1103.
Meisel R., Brockers S., Heseler K., et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011, 25:648-654.
Li H., Guo Z., Jiang X., Zhu H., Li X., Mao N. Mesenchymal stem cells alter migratory property of T and dendritic cells to delay the development of murine lethal acute graft-versus-host disease. Stem Cells 2008, 26:2531-2541.
Polchert D., Sobinsky J., Douglas G., et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 2008, 38:1745-1755.
Prigozhina T.B., Khitrin S., Elkin G., Eizik O., Morecki S., Slavin S. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation. Exp Hematol 2008, 36:1370-1376.
Yanez R., Lamana M.L., Garcia-Castro J., Colmenero I., Ramirez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006, 24:2582-2591.
Badillo A.T., Peranteau W.H., Heaton T.E., Quinn C., Flake A.W. Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease. Br J Haematol 2008, 141:224-234.
Christensen M.E., Turner B.E., Sinfield L.J., et al. Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-versus-host disease. Haematologica 2010, 95:2102-2110.
Tisato V., Naresh K., Girdlestone J., Navarrete C., Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 2007, 21:1992-1999.
Bruck F., Lechanteur C., De leval L., et al. IP co-transplantation of mesenchymal stem cells (MSC) failed to prevent acute GVHD in a humanized mice model. Exp Hematol 2009, 37:S87-S88.
Reddy P., Negrin R., Hill G.R. Mouse models of bone marrow transplantation. Biol Blood Marrow Transplant 2008, 14:129-135.
Chu Y.W., Gress R.E. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant 2008, 14:365-378.
Storb R., Thomas E.D. The scientific foundation of marrow transplantation based on animal studies. Bone Marrow Transplantation 1994, 3-11. Blackwell Scientific Publications, Boston, MA. S.J. Forman, K.G. Blume, E.D. Thomas (Eds.).
Lee W.S., Suzuki Y., Graves S.S., et al. Canine bone marrow derived mesenchymal stromal cells suppress allo-reactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation. Biol Blood Marrow Transplant 2011, 17:465-475.
Storb R., Yu C., Wagner J.L., et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-3054.
Hogan W.J., Little M.-T., Zellmer E., et al. Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biol Blood Marrow Transplant 2003, 9:489-495.
Baron F., Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 2006, 13:26-41.
Storb R., Yu C., Zaucha J.M., et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999, 94:2523-2529.
Jochum C., Beste M., Zellmer E., Graves S.S., Storb R. CD154 blockade and donor-specific transfusions in DLA-identical marrow transplantation in dogs conditioned with 1-Gy total body irradiation. Biol Blood Marrow Transplant 2007, 13:164-171.
Storb R., Yu C., Barnett T., et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999, 94:1131-1136.
Bethge W.A., Wilbur D.S., Storb R., et al. Selective T-cell ablation with bismuth-213-labeled anti-TCRab as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003, 101:5068-5075.
Baron F., Sandmaier B.M., Zellmer E., Sorror M., Storer B., Storb R. Failure of donor lymphocyte infusion to prevent graft rejection in dogs given DLA-identical marrow after 1 Gy of total body irradiation. Biol Blood Marrow Transplant 2006, 12:813-817.
Horwitz E.M., Maziarz R.T., Kebriaei P. MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:S21-S29.
Horwitz E.M., Dominici M. How do mesenchymal stromal cells exert their therapeutic benefit?. Cytotherapy 2008, 10:771-774.
Mets T., Verdonk G. In vitro aging of human bone marrow derived stromal cells. Mech Ageing Dev 1981, 16:81-89.
Lee R.H., Seo M.J., Pulin A.A., Gregory C.A., Ylostalo J., Prockop D.J. The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood 2009, 113:816-826.
Bernardo M.E., Zaffaroni N., Novara F., et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 2007, 67:9142-9149.
Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
Kebriaei P., Isola L., Bahceci E., et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009, 15:804-811.
Haynesworth S.E., Baber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592.
Prasad V.K., Lucas K.G., Kleiner G.I., et al. Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (ProchymalTM) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 2011, 17:534-541.
Le Blanc K., Samuelsson H., Lonnies L., Sundin M., Ringden O. Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. Transplantation 2007, 84:1055-1059.
Lucchini G., Introna M., Dander E., et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol Blood Marrow Transplant 2010, 16:1293-1301.
Perez-Simon J.A., Lopez-Villar O., Andreu E.J., et al. Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial. Haematologica 2011, 96:1072-1076.
Wagner W., Wein F., Seckinger A., et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005, 33:1402-1416.
Wagner W., Feldmann R.E., Seckinger A., et al. The heterogeneity of human mesenchymal stem cell preparations-evidence from simultaneous analysis of proteomes and transcriptomes. Exp Hematol 2006, 34:536-548.
Simmons P.J., Przepiorka D., Thomas E.D., Torok-Storb B. Host origin of marrow stromal cells following allogeneic bone marrow transplantation. Nature 1987, 328:429-432.
Awaya N., Rupert K., Bryant E., Torok-Storb B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 2002, 30:937-942.
Pozzi S., Lisini D., Podesta M., et al. Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Exp Hematol 2006, 34:934-942.
Koc O.N., Gerson S.L., Cooper B.W., et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000, 18:307-316.
Lazarus H.M., Koc O.N., Devine S.M., et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005, 11:389-398.
MacMillan M.L., Blazar B.R., Defor T.E., Wagner J.E. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial. Bone Marrow Transplant 2009, 43:447-454.
Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110:2764-2767.
Bernardo M.E., Ball L.M., Cometa A.M., et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011, 46:200-207.
Ning H., Yang F., Jiang M., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 2008, 22:593-599.
Baron F., Lechanteur C., Willems E., et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant 2010, 16:838-847.
Cragg L., Blazar B.R., DeFor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 2000, 6:441-447.
Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004, 104:1559-1564.
Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009, 114:511-517.
Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol 2009, 27:966-967.
Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
von Bahr L., Sundberg B., Lonnies H., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2011.
Kurtzberg J., Prasad V., Grimley M.S., et al. Allogeneic human mesenchymal stem cell therapy (Prochymal®) as a rescue agent for severe treatment resistant GVHD in pediatric patients. Biol Blood Marrow Transplant 2010, 16. s169.
von Bonin M., Stolzel F., Goedecke A., et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant 2009, 43:245-251.
Martin P.J., Uberti J.P., Soiffer R.J., et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010, 16:S169-S170.
Fang B., Song Y., Liao L., Zhang Y., Zhao R.C. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007, 39:3358-3362.
Zhou H., Guo M., Bian C., et al. Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010, 16:403-412.
Weng J.Y., Du X., Geng S.X., et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant 2010, 45:1732-1740.
Samuelsson H., Ringden O., Lonnies H., Le Blanc K. Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. Cytotherapy 2009, 11:129-136.

Similar publications